Informational Shocks, Off-Label Prescribing, and the Effects of Physician Detailing

References

• Anderson TS, Huskamp HA, Epstein AJ, Barry CL, Men A, Berndt ER, Horvitz-Lennon M, Normand SL, Donohue JM (2015) Antipsychotic prescribing: Do conflict of interest policies make a difference? Medical Care 53(4):338–345.Crossref, Google Scholar
• Arana GW (2000) An overview of side effects caused by typical anti-psychotics. J. Clinical Psychiatry 61(8):5–11.Google Scholar
• Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4):551–594.Crossref, Google Scholar
• Berndt ER, Bui L, Reiley DR, Urban GL (1995) Information, marketing, and pricing in the US antiulcer drug market. Amer. Econom. Rev. 85(2):100–105.Google Scholar
• Berndt ER, Bui L, Reiley DR, Urban GL (1997) The roles of price, quality, and marketing in the growth and composition of the antiulcer drug market. Bresnahan TF, Gordon RJ, eds. The Economics of New Goods, NBER Studies in Income and Wealth, Vol. 58 (University of Chicago Press, Chicago), 277–322.Google Scholar
• Bradford WD, Turner JL, Williams JW (2015) Off-label use of pharmaceuticals: A detection controlled estimation approach. Working paper, University of Georgia, Athens.Google Scholar
• Ching A, Ishihara M (2010) The effects of detailing on prescribing decisions under quality uncertainty. Quant. Marketing Econom. 8(2):123–165.Crossref, Google Scholar
• Ching AT, Clark R, Horstmann I, Lim H (2015) The effects of publicity on demand: The case of anti-cholesterol drugs. Marketing Sci. 35(1):158–181.Google Scholar
• Chintagunta PK, Goettler RL, Kim M (2012) New drug diffusion when forward-looking physicians learn from patient feedback and detailing. J. Marketing Res. 49(6):807–821.Crossref, Google Scholar
• Datta A, Dave D (2016) Effects of physician-directed pharmaceutical promotion on prescription behaviors: Longitudinal evidence. Health Econom. 26(4):450–468.Crossref, Google Scholar
• Dong X, Manchanda P, Chintagunta PK (2009) Quantifying the benefits of individual-level targeting in the presence of firm strategic behavior. J. Marketing Res. 46(2):207–221.Crossref, Google Scholar
• Dong X, Chintagunta PK, Manchanda P (2011) A new multivariate count data model to study multi-category physician prescription behavior. Quant. Marketing Econom. 9(3):301–337.Crossref, Google Scholar
• Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, Tamblyn R (2016) Association of off-label drug use and adverse drug events in an adult population. JAMA Internal Medicine 176(1):55–63.Crossref, Google Scholar
• Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, Benser M, Edmondson AC, Bates DW (2000) Incidence and preventability of adverse drug events in nursing homes. Amer. J. Medicine 109(2):87–94.Crossref, Google Scholar
• Iyengar R, Van den Bulte C, Valente TW (2011) Opinion leadership and social contagion in new product diffusion. Marketing Sci. 30(2):195–212.Link, Google Scholar
• Larkin I, Ang D, Avorn J, Kesselheim AS (2014) Restrictions On pharmaceutical detailing reduced off-label prescribing of antidepressants and anti-psychotics in children. Health Affairs 33(6):1014–1023.Crossref, Google Scholar
• Liu H, Liu Q, Chintagunta PK (2017) Promotion spillovers: Drug detailing in combination therapy. Marketing Sci. 36(3):382–401.Link, Google Scholar
• Manchanda P, Rossi PE, Chintagunta PK (2004) Response modeling with nonrandom marketing-mix variables. J. Marketing Res. 41(4):467–478.Crossref, Google Scholar
• Mizik N, Jacobson R (2004) Are physicians “easy marks”? Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. 50(12):1704–1715.Link, Google Scholar
• Montoya R, Netzer O, Jedidi K (2010) Dynamic allocation of pharmaceutical detailing and sampling for long-term profitability. Marketing Sci. 29(5):909–924.Link, Google Scholar
• Narayanan S, Manchanda P (2009) Heterogeneous learning and the targeting of marketing communication for new products. Marketing Sci. 28(3):424–441.Link, Google Scholar
• Narayanan S, Desiraju R, Chintagunta PK (2004) Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. J. Marketing 68(4):90–105.Crossref, Google Scholar
• Narayanan S, Manchanda P, Chintagunta PK (2005) Temporal differences in the role of marketing communication in new product categories. J. Marketing Res. 42(3):278–290.Crossref, Google Scholar
• Rao A, Wang E (2017) Demand for “healthy” products: False claims and FTC regulation. J. Marketing Res. 54(6):968–989.Crossref, Google Scholar
• Ray WA, Federspiel CF, Schaffner W (1980) A study of anti-psychotic drug use in nursing homes: Epidemiologic evidence suggesting misuse. Amer. J. Public Health 70(5):485–491.Crossref, Google Scholar
• Shapiro BT (2018) Positive spillovers and free-riding in advertising of prescription pharmaceuticals: The case of antidepressants. J. Political Econom. 126(1).Crossref, Google Scholar
• Sood A, Kappe E, Stremersch S (2014) The commercial contribution of clinical studies for pharmaceutical drugs. Internat. J. Res. Marketing 31(1):65–77.Crossref, Google Scholar
• Stremersch S, Lemmens A (2009) Sales growth of new pharmaceuticals across the globe: The role of regulatory regimes. Marketing Sci. 28(4):690–708.Link, Google Scholar
• Venkataraman S, Stremersch S (2007) The debate on influencing doctors’ decisions: Are drug characteristics the missing link? Management Sci. 53(11):1688–1701.Link, Google Scholar